Trial · NCT02101021
Results by group25
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 25
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Lead-In Phase: Percentage of Participants Experiencing Treatment-Emergent Dose Limiting Toxicity (DLT) Adverse Events | MMB Dose Level 1 | 16.7 | percentage of participants | ||
| Lead-In Phase: Percentage of Participants Experiencing Treatment-Emergent Dose Limiting Toxicity (DLT) Adverse Events | MMB Dose Level 2 | 0 | percentage of participants | ||
| Lead-In Phase: Percentage of Participants Experiencing Treatment-Emergent Dose Limiting Toxicity (DLT) Adverse Events | MMB Dose Level 3 | 16.7 | percentage of participants | ||
| Lead-In Phase: Percentage of Participants Experiencing Treatment-Emergent Dose Limiting Toxicity (DLT) Adverse Events | MMB Dose Level 4 | 0 | percentage of participants | ||
| Lead-In Phase: Percentage of Participants Experiencing Treatment-Emergent Dose Limiting Toxicity (DLT) Adverse Events | MMB Dose Level 5 | 0 | percentage of participants | ||
| Lead-In Phase: Overall Survival (OS) | MMB Dose Level 1 | 12.4 | Inter-Quartile Range 3.9 to 22.2 | Months | |
| Lead-In Phase: Overall Survival (OS) | MMB Dose Level 2 | 5.1 | Inter-Quartile Range 3.7 to 11.3 | Months | |
| Lead-In Phase: Overall Survival (OS) | MMB Dose Level 3 | 8.7 | Inter-Quartile Range 7.3 to 18.3 | Months | |
| Lead-In Phase: Overall Survival (OS) | MMB Dose Level 4 | 5.6 | Inter-Quartile Range 4.8 to 18.1 | Months | |
| Lead-In Phase: Overall Survival (OS) | MMB Dose Level 5 | 7.1 | Inter-Quartile Range 5.9 to 12.0 | Months | |
| Lead-In Phase: Progression-Free Survival (PFS) | MMB Dose Level 1 | 5.3 | Inter-Quartile Range 1.4 to 7.4 | Months | |
| Lead-In Phase: Progression-Free Survival (PFS) | MMB Dose Level 2 | 3.2 | Inter-Quartile Range 1.9 to 4.8 | Months | |
| Lead-In Phase: Progression-Free Survival (PFS) | MMB Dose Level 3 | 5.5 | Inter-Quartile Range 5.3 to 7.2 | Months | |
| Lead-In Phase: Progression-Free Survival (PFS) | MMB Dose Level 4 | 5.3 | Inter-Quartile Range 0.0 to 13.0 | Months | |
| Lead-In Phase: Progression-Free Survival (PFS) | MMB Dose Level 5 | 5.5 | Inter-Quartile Range 4.5 to 10.1 | Months | |
| Lead-In Phase: Overall Response Rate (ORR) | MMB Dose Level 1 | Complete Response (CR) | 2 | Participants | |
| Lead-In Phase: Overall Response Rate (ORR) | MMB Dose Level 2 | Complete Response (CR) | 1 | Participants | |
| Lead-In Phase: Overall Response Rate (ORR) | MMB Dose Level 3 | Complete Response (CR) | 3 | Participants | |
| Lead-In Phase: Overall Response Rate (ORR) | MMB Dose Level 4 | Complete Response (CR) | 1 | Participants | |
| Lead-In Phase: Overall Response Rate (ORR) | MMB Dose Level 5 | Complete Response (CR) | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02101021/results